abetimus

Trade name: Riquent

Small moleculeexperimental

Abetimus is an immunosuppressant. It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies. It may also complex anti dsDNA antibodies together, therefore disabling them. This way abetimus was supposed to help treat systemic lupus erythematosus and specifically lupus nephritis. — Wikipedia

Clinical trial activity

3 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started May 2, 2002 (NCT00035308)

Timeline

2000s

Jan 1, 2002
Earliest Phase 3 Sponsor(trial)
Jan 1, 2006
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

dsDNA antibodiesINHIBITOR
dsDNA antibodies inhibitor
dsDNA antibodiesImmunity, passive
dsDNA antibodies immunity, passive

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

abetimus
abetimus sodium
abetimus sodium
abetimus sodium
ljp 394
ljp-394
ljp-394

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00390091	Phase 2	Sep 1, 2006	La Jolla Pharmaceutical Company
NCT00089804	Phase 3	Oct 1, 2004	La Jolla Pharmaceutical Company
NCT00035308	Phase 3	May 2, 2002	La Jolla Pharmaceutical Company

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
La Jolla Pharmaceutical Company	For profit	3	3	2	2002

1 organizations

Page 1 / 1